Roche posts pos­i­tive PhII re­sults for bis­pe­cif­ic an­ti­body eye drug, join­ing No­var­tis in ri­val­ry with Eylea

As No­var­tis bat­tles Re­gen­eron for a piece of its block­buster Eylea fran­chise, Roche/Genen­tech $RHH­BY is com­ing up qui­et­ly with a next-gen bis­pe­cif­ic an­ti­body which post­ed en­cour­ag­ing Phase II re­sults late Sun­day.

RG7716 is a dual an­ti-VEGF/an­ti-an­giopoi­etin-2 an­ti­body that tar­gets reti­nal eye dis­eases. The BOULE­VARD study com­pared two dos­es of it to Roche’s own VEGF-tar­get­ing ranibizum­ab (Lu­cen­tis) and found a sig­nif­i­cant im­prove­ment in ad­just­ed best cor­rect­ed vi­su­al acu­ity (BC­VA), there­by meet­ing its pri­ma­ry end­point. The ad­just­ed mean im­prove­ment are 13.9 chart let­ters from base­line for pa­tients giv­en 6 mg RG7716; 11.7 let­ters for those giv­en 1.5 mg RG7716; and 10.3 among those dosed with 0.3 mg ranibizum­ab, re­spec­tive­ly. The p-val­ue came in at 0.03.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER